Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 1/20 | 0.55 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL254969 | 0.84 | ALDH1A1 (0.56) | KEAP1TSHROPRM1OPRD1HPGD | |
| SCHEMBL3442880 | 0.83 | ESR1 (0.56) | KEAP1TSHROPRM1OPRD1HPGD | |
| SCHEMBL7219292 | 0.81 | KEAP1 (0.48) | KEAP1TSHROPRM1OPRD1HPGD | |
| SCHEMBL2941369 | 0.81 | HPGD (0.56) | KEAP1TSHROPRM1OPRD1HPGD | |
| SCHEMBL3312574 | 0.79 | KEAP1 (0.49) | KEAP1TSHRHPGDALDH1A1TP53 | |
| SCHEMBL1706516 | 0.79 | MMP2 (0.55) | KEAP1TSHRHPGDALDH1A1TP53 | |
| SCHEMBL7852399 | 0.79 | KEAP1 (0.46) | KEAP1TSHROPRM1OPRD1HPGD | |
| SCHEMBL10652028 | 0.79 | KEAP1 (0.46) | KEAP1TSHROPRM1OPRD1HPGD | |
| SCHEMBL12086326 | 0.78 | TDP1 (0.61) | KEAP1OPRM1OPRD1HPGDALDH1A1 | |
| SCHEMBL14052340 | 0.78 | KEAP1 (0.55) | KEAP1TSHROPRM1OPRD1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190218219-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-07-18 | — | — | US | claimed |
| US-20260098040-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA CELLULAR THERAPIES INC (US) | 2026-04-09 | — | — | US | disclosed |
| EP-3609891-B1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA CELLULAR THERAPIES INC (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-3898581-B1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA CELLULAR THERAPIES INC (US) | 2025-08-27 | — | — | EP | disclosed |
| US-12358916-B2 | Substituted heterocycle fused gamma-carbolines synthesis | INTRA-CELLULAR THERAPIES, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| US-12297200-B2 | Substituted heterocycle fused gamma-carbolines synthesis | INTRA-CELLULAR THERAPIES, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-20250101022-A1 | PROCESS FOR PREPARING INTERMEDIATES FOR 1-(4-FLUOROPHENYL)-4-((6bR,10aS)-3-METHYL-2,3,6b,9,10,10a-HEXAHYDRO-1H-PYRIDO[3’,4’:4,5]PYRROLO[1,2,3-de]QUINOXALIN-8(7H)-YL)BUTAN-1-ONE | INTRA-CELLULAR THERAPIES, INC. (US) | 2025-03-27 | — | — | US | disclosed |
| US-12139490-B2 | Process for preparing 1-(4-fluorophenyl)-4-((6bR, 10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)butan-1-one | INTRA-CELLULAR THERAPIES, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| US-20240327409-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA-CELLULAR THERAPIES, INC. | 2024-10-03 | — | — | US | disclosed |
| CN-113227045-B | Synthesis of substituted heterocycle fused gamma-carbolines | 细胞内治疗公司 | 2024-04-26 | — | — | CN | disclosed |
| US-9751883-B2 | Preparation of certain [((6BR,10AS)-2,3,6B,7,8,9,10, 10A-octahydro-1H-pyrido[3′,4′:4,5]pyrrolo [1,2,3-de]quinoxalines and pharmaceutically acceptable salts thereof | INTRA-CELLULAR THERAPIES, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20160194326-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA-CELLULAR THERAPIES, INC. | 2016-07-07 | — | — | US | disclosed |
| US-9315504-B2 | Preparation of 4-((6BR,10AS)-3-methyl-2,3,6B,9,10, 10A-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo [1,2,3-de]quinoxalin-8-(7H)-yl)-1-(4-fluorophenyl)-1-butanone or a pharmaceutically acceptable salt thereof | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-20140364609-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA-CELLULAR THERAPIES, INC. | 2014-12-11 | — | — | US | disclosed |
| US-8779139-B2 | Substituted 2,3,4,4A,5,9B-hexahydro-1H-pyrido[4,3-B]indole derivatives synthesis and uses thereof | INTRA-CELLULAR THERAPIES, INC. | 2014-07-15 | — | — | US | disclosed |
| US-20130046097-A1 | SUBSTITUTED HETEROCYCLE GAMMA-CARBOLINES SYNTHESIS | INTRA-CELLULAR THERAPIES, INC. | 2013-02-21 | — | — | US | disclosed |
| US-8309722-B2 | Substituted heterocycle gamma-carbolines synthesis | INTRA-CELLULAR THERAPIES, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20100113781-A1 | SUBSTITUTED HETEROCYCLE GAMMA-CARBOLINES SYNTHESIS | INTRACELLULAR THERAPIES, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| EP-2134710-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | Intra-Cellular Therapies, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008112280-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA-CELLULAR THERAPIES, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218219-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | CYCS, HCCS, IDH3B | ALB 3258/4885KEAP1 2112/4885TSHR 3293/4885 |
| US-12358916-B2 | Substituted heterocycle fused gamma-carbolines synthesis | HCCS, CYCS, CBR3 | ALB 3393/4885KEAP1 2506/4885TSHR 3270/4885 |
| US-20240327409-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | HCCS, CYCS, CBR3 | ALB 3393/4885KEAP1 2506/4885TSHR 3270/4885 |
| US-20250101022-A1 | PROCESS FOR PREPARING INTERMEDIATES FOR 1-(4-FLUOROPHENYL)-4-((6bR,10aS)-3-METHYL-2,3,6b,9,10,10a-HEXAHYDRO-1H-PYRIDO[3’,4’:4,5]PYRROLO[1,2,3-de]QUINOXALIN-8(7H)-YL)BUTAN-1-ONE | CYP1B1, CYP4B1, CBR1 | ALB 3657/4885KEAP1 640/4885TSHR 2882/4885 |
| US-20100113781-A1 | SUBSTITUTED HETEROCYCLE GAMMA-CARBOLINES SYNTHESIS | CYCS, HCCS, CBR3 | ALB 3529/4885KEAP1 1855/4885TSHR 3099/4885 |
| US-20160194326-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | HCCS, CYCS, CBR3 | ALB 3436/4885KEAP1 2398/4885TSHR 3322/4885 |
| US-20140364609-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | HCCS, CYCS, CBR3 | ALB 3370/4885KEAP1 2339/4885TSHR 3274/4885 |
| US-20260098040-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | KCNH2, KCNH3, KCNH1 | ALB 3699/4885KEAP1 676/4885TSHR 585/4885 |
| US-20130046097-A1 | SUBSTITUTED HETEROCYCLE GAMMA-CARBOLINES SYNTHESIS | CYCS, HCCS, CBR3 | ALB 3529/4885KEAP1 1855/4885TSHR 3099/4885 |
| US-12297200-B2 | Substituted heterocycle fused gamma-carbolines synthesis | HCCS, CYCS, CBR3 | ALB 3393/4885KEAP1 2506/4885TSHR 3270/4885 |
| US-12139490-B2 | Process for preparing 1-(4-fluorophenyl)-4-((6bR, 10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)butan-1-one | CYP1B1, CYP4B1, CBR1 | ALB 3432/4885KEAP1 521/4885TSHR 2504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.